We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tafinlar

News List

Novartis’ Tafinlar plus Mekinist shows long-term benefit in advanced melanoma pharmatimes
September 18, 2020
A combination of Novartis’ cancer meds Tafinlar (dabrafenib) and Mekinist (trametinib) has demonstrated long-term benefit in advanced melanoma patients after five years of treatment.
Novartis' melanoma combo fails in PhIII pharmatimes
August 24, 2020
Novartis has announced that its investigational immunotherapy spartalizumab in combination with Tafinlar (dabrafenib) and Mekinist (trametinib) failed to improve progression-free survival in patients with advanced melanoma.
FiercePharmaAsia—Sun’s quarterly loss, BeiGene’s $175M public offering, Biocon plant’s extensive pro fiercepharma
August 14, 2017
Sun Pharma took a hit with a 9.51 billion rupees antitrust settlement over Modafinil, a sleep disorder treatment.